Table 2 Meta-analysis of the APOA5 -1131T>C polymorphism and blood lipids association (excluding the outlier studies)

LDL-C

   All

34

0.28

0.03 (-0.01, 0.06)

0.12

   All in HWE

31

0.28

0.02 (-0.02, 0.06)

0.34

   No lipid-lowering medicine

15

0.76

-0.00 (-0.06, 0.06)

0.94

   No lipid-lowering medicine in HWE

14

0.69

-0.00 (-0.06, 0.06)

0.96

   European

10

0.26

0.05 (-0.04, 0.13)

0.27

   European in HWE

8

0.14

0.05 (-0.06, 0.16)

0.38

   East Asian

18

0.24

0.02 (-0.03, 0.07)

0.37

   East Asian in HWE

17

0.40

0.00 (-0.05, 0.06)

0.87

   Healthy

7

0.18

-0.00 (-0.11, 0.11)

0.98

   Type 2 diabetes

7

0.36

-0.01 (-0.11, 0.10)

0.89

   Male

4

0.14

0.01 (-0.17, 0.19)

0.94

   Male in HWE

3

0.07

-0.01 (-0.30, 0.29)

0.96

HDL-C

   All

44

0.55

-0.15 (-0.18, -0.13)

<0.00001

   All in HWE

41

0.66

-0.15 (-0.17, -0.12)

<0.00001

   No lipid-lowering medicine

21

0.66

-0.15 (-0.20, -0.10

<0.00001

   No lipid-lowering medicine in HWE

20

0.61

-0.15 (-0.20, -0.10)

<0.00001

   European

12

0.46

-0.11 (-0.17, -0.05)

0.0005

   European in HWE

10

0.29

-0.12 (-0.20, -0.04)

0.005

   East Asian

23

0.71

-0.18 (-0.21, -0.15)

<0.00001

   East Asian in HWE

22

0.80

-0.17 (-0.20, -0.13)

<0.00001

   Other

9

0.74

-0.10 (-0.16, -0.03)

0.004

   CHD

4

0.61

-0.12 (-0.23, -0.01)

0.04

   CHD in HWE

3

0.42

-0.12 (-0.24, -0.01)

0.04